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Ferumoxtran-10 enhanced MR imaging in detection of metastases
outside the normal surgical area in prostate cancer
J.O. Barentsz, R. Heesakkers, A.Hovels, F. Witjes, B. Knipscheer,
P. MUlders and C. Hulsbergen
Departments of Radiology, Urology and Pathology. University Medical
Center St. Radboud, Nijmegen, The Netherlands
Rationale and Objectives: To evaluate whether, in prostate cancer
patients, with Ferumoxtran-10 enhanced MR imaging lymph node
metastases outside the normal surgical area (that is, the obturator fossa)
will be detected.
Methods: A total of 150 consecutive patients with prostate cancer and
at intermediate to high risk for nodal metastases (PSA >10 or Gleason
< 6 or at DRE stage T3) were enrolled in this study. At 1.5 T, T1- and
T2
-weighted MR images of the pelvis were obtained, 24 h after
administration of Ferumoxtran-10. The MR examinations were
evaluated by one experienced reader.
Lymph node metastases were conﬁrmed by lymph node dissection or
CT-guided lymph node biopsy
Results: Thirty-one1 out of 150 patients (21%) had positive lymph
nodes conﬁrmed by histopathology. Of these 31 patients, 16 (52%) had
positive lymph nodes only outside the normal surgical area (obturator
fossa), eight (26%) had positive nodes inside and outside the obturator
fossa and six (19%) only inside. Without Ferumoxtran-10 enhanced
MRI, in 52% of the patients these positive nodes would not have been
detected.
Conclusion: With Ferumoxtran-10 enhanced MR imaging, additional
nodes will be found compared with obturator nodal dissection.
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MRI tumor characterization using Gd–GlyMe–DOTA-
perﬂuorooctylmannose conjugate (Gadoﬂuorine M), a novel
protein-avid contrast agent
R. Brasch,1 H.-J. Raatschen,1 Z. Boyd,1 D. Shames,1 M. Zierhut,1
R. Swain,1 B. Misselwitz,2 H. Weinmann2 and M. Wendland1
1Center for Pharmaceutical and Molecular Imaging, University of
California, San Francisco, CA, USA
2MRI Research and Development Unit, Schering AG, Berlin, Germany
Rationale and Objectives: The aim was to deﬁne the pharmacoki-
netics and MRI tumor-enhancing characteristics of a new protein-avid
contrast agent, Gd–GlyMe–DOTA–perﬂuorooctylmannose conjugate
(Gadoﬂuorine M, Schering, Berlin, Germany) in a chemically induced
tumormodel of varyingmalignancy. Because of the unique properties of
this agent, including a large effective in vivo hydrodynamic radius (5.5
nm) and strong binding to hydrophobic sites on extracellular proteins, it
was hypothesized that patterns of dynamic enhancement in tumors
could be used to measure abnormal tumor microvascular permeabilities
and also could aid in the differentiation of viable and necrotic tumor
components.
Methods: Gadoﬂuorine M, 0.1 mmol Gd/kg, was administered
intravenously to 32 anesthetized rats that had developed mammary
tumors of varying degrees of malignancy over the 6 months following
intraperitoneal administration of N-ethylnitrosourea (ENU), 45–250
mg. These tumors ranged pathologically from benign ﬁbroadenomas to
highly undifferentiated adenocarcinomas. Pre- and dynamic post-
contrast T1-weighted MRI at 2.0 T (Bruker) was performed at
short intervals for 40 min with region-of-interest analyses of whole
tumor, tumor rim, tumor center and venous blood enhancement
responses. These enhancement data were also post-processed using
a two-compartment kinetic model to generate estimates of fra-
ctional plasma volumes (fPV) and the apparent coefﬁcient of
permeability–surface area product (KPS). After killing the animals, the
tumors were examined microscopically and scored by a pathologist,
blinded to the MRI data, for tumor type, degree of malignancy (Scarff–
Bloom–Richardson score), plus degree and distribution of necrosis.
Pathological data were correlated with MRI observations.
Results: So far 26 tumor-bearing rats have now been successfully
examined by dynamicMRI,with another 8–10 animals to be added by the
time of presentation. Accumulated data show an immediate strong but
gradually increasing tumor enhancement,with the late enhancement being
concentrated in the tumor center, a zone of relatively greater necrosis.
Complete data analyses with calculation of fPV, KPS and paired tumor
MRI–pathology correlations will be available at the time of presentation.
Conclusions: A novel MRI contrast agent, Gadoﬂuorine M, strongly
enhances tumors of varying pathology and on late images seems to
highlight zones of necrosis, probably owing to a strong avidity for
hydrophobic sites on extracellular proteins. Because this 1528 Da
molecule tends to form aggregates with hydrodynamic diameters of >5
nm after intravenous administration, dynamic enhancement can also be
used to assay tumor plasma volumes.
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The stromal mechanism: an inherent link between necrosis-avid
contrast agents and photodynamic therapy
Y. Ni.1 F. Chen,1 G. Bormans,2 A. Verbruggen2 and G. Marchal1
1Department of Radiology, Catholic University of Leuven, Belgium
2Department of Radiopharmaceutics, Catholic University of Leuven,
Belgium
Rationale and Objectives: Necrosis-avid contrast agents (NACAs)
were discovered initially among porphyrin derivatives including
gadophrin-2 that were intended to target neoplastic cells with the same
principle adopted from cancer photodynamic therapy (PDT). Later, the
NACAs of non-porphyrin chemicals including ECIII-60 and ECIV-7
were developed with demonstrated multifunctional features such as
striking T1 and T2 dual-contrast enhancement of acute myocardial
infarction, therapeutic assessment after tumor ablation, blood-pool
effect for MR angiography and hepatobiliary tumor detection (1). Here
we sought to investigate the underlying mechanisms of NACAs and to
formulate consequent new diagnostic and therapeutic strategies.
Methods:
1. Summarizing experimental results derived from MRI, SPECT,
autoradiography, radioactivity counting and ﬂuorescent and optical
microscopy studies in animalmodels of induced tumors and necroses
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